Literature DB >> 6189578

Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin.

T R Koch, K M Lichtenfeld, P H Wiernik.   

Abstract

Beta-2-microglobulin determinations in cerebrospinal fluid (CSF) of patients with leukemia, lymphoma, and oat cell carcinoma were performed to evaluate the utility of this test in early detection of metastasis to the central nervous system (CNS). In the presence of CNS disease, significantly higher levels (P less than 0.001) were found than in normals or patients without CNS disease. Serial measurements were performed on two patients, and in all cases beta-2-microglobulin became elevated coincident with CNS relapse, and returned to normal as remission was achieved. Serial testing of CSF beta-2-microglobulin, in patients with cancers known to invade the CNS, should facilitate prompt treatment of CNS metastasis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6189578     DOI: 10.1002/1097-0142(19830701)52:1<101::aid-cncr2820520119>3.0.co;2-y

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

1.  Library subtraction of in vitro cDNA libraries to identify differentially expressed genes in scrapie infection.

Authors:  J R Duguid; M C Dinauer
Journal:  Nucleic Acids Res       Date:  1990-05-11       Impact factor: 16.971

2.  Increased beta 2-microglobulin in CSF of multiple sclerosis.

Authors:  J C Alvarez-Cermeño; L M Villar; G Roy; A Ferreira; A Bootello; A Gimeno; P González-Porqué
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-09       Impact factor: 10.154

Review 3.  Malignancy markers in the cerebrospinal fluid.

Authors:  M Koskiniemi
Journal:  Eur J Pediatr       Date:  1988-10       Impact factor: 3.183

4.  Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.

Authors:  Fatima W Khwaja; Matthew S Reed; Jeffrey J Olson; Brian J Schmotzer; G Yancey Gillespie; Abhijit Guha; Morris D Groves; Santosh Kesari; Jan Pohl; Erwin G Van Meir
Journal:  J Proteome Res       Date:  2007-02       Impact factor: 4.466

5.  Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors.

Authors:  A Twijnstra; B W Ongerboer de Visser; A P van Zanten; A A Hart; W J Nooyen
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

6.  Immunosuppressive acidic protein in patients with brain tumours: a preliminary report.

Authors:  K Kikuchi; H Gotoh; M Kowada
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

7.  Serial lumbar and ventricle cerebrospinal fluid lactate dehydrogenase activities in patients with leptomeningeal metastases from solid and haematological tumours.

Authors:  A Twijnstra; A P van Zanten; A A Hart; B W Ongerboer de Visser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-03       Impact factor: 10.154

Review 8.  A systematic approach to the diagnosis of suspected central nervous system lymphoma.

Authors:  Brian J Scott; Vanja C Douglas; Tarik Tihan; James L Rubenstein; S Andrew Josephson
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

9.  Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer.

Authors:  A Twijnstra; A P van Zanten; W J Nooyen; B W Ongerboer de Visser
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-11       Impact factor: 10.154

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.